RT Journal Article
SR Electronic
T1 The impacts of COVID-19 vaccine timing, number of doses, and risk prioritization on mortality in the US
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.18.21250071
DO 10.1101/2021.01.18.21250071
A1 Wang, Xutong
A1 Du, Zhanwei
A1 Johnson, Kaitlyn E.
A1 Fox, Spencer J.
A1 Lachmann, Michael
A1 McLellan, Jason S.
A1 Meyers, Lauren Ancel
YR 2021
UL http://medrxiv.org/content/early/2021/01/20/2021.01.18.21250071.abstract
AB As COVID-19 vaccination begins worldwide, policymakers face critical trade-offs. Using a mathematical model of COVID-19 transmission, we find that timing of the rollout is expected to have a substantially greater impact on mortality than risk-based prioritization and adherence and that prioritizing first doses over second doses may be life saving.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by NIH Grant R01 AI151176 and CDC Grant U01 IP00136.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA